Ocugen, Inc/$OCGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ocugen, Inc

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ticker

$OCGN
Sector
Primary listing

Employees

95

Ocugen, Inc Metrics

BasicAdvanced
$534M
-
-$0.20
3.85
-

What the Analysts think about Ocugen, Inc

Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.

Bulls say / Bears say

Ocugen will present its innovative modifier gene therapy platform, including Phase 3 data for OCU400, the Phase 2/3 program for OCU410ST, and Phase 2 results for OCU410 at ARVO 2025 and Retina World Congress, highlighting strong clinical progress.
The first patient was dosed in the Phase 2/3 GARDian3 trial for OCU410ST in Stargardt disease on July 18, 2025, marking an important late-stage milestone for a key pipeline candidate.
Ocugen signed a binding term sheet for exclusive Korean licensing rights to OCU400, unlocking up to $11 million in upfront and milestone payments and opening new commercialization opportunities.
Cash, cash equivalents, and restricted cash were only $27.3 million as of June 30, 2025, providing funding into Q1 2026 and indicating a risk of near-term dilutive financing.
The accumulated deficit reached $370.3 million as of June 30, 2025, reflecting large historical losses and ongoing financial challenges.
Lead pipeline assets face long development timelines, with OCU400's BLA/MAA filings not expected until mid-2026 and OCU410ST's BLA planned for 2027, delaying possible revenue and raising regulatory risk.
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2025.

Ocugen, Inc Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ocugen, Inc Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OCGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs